Related references
Note: Only part of the references are listed.Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group
Jelena Bila et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Prostaglandin E2 in a TLR3-and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8+ T cells
Philipp Gierlich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Pinto et al.
CANCERS (2020)
Multiple Myeloma: What Do We Do About Immunodeficiency?
Linrong Li et al.
JOURNAL OF CANCER (2019)
The cryo-thermal therapy-induced IL-6-rich acute pro-inflammatory response promoted DCs phenotypic maturation as the prerequisite to CD4+ T cell differentiation
Kun Liu et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2018)
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Brian A. Walker et al.
BLOOD (2018)
Mycobacterium tuberculosis protein Rv2220 induces maturation and activation of dendritic cells
Seunga Choi et al.
CELLULAR IMMUNOLOGY (2018)
Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy
Prajakta Shinde et al.
SCIENTIFIC REPORTS (2018)
Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation
Christian Bull et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Multiple Myeloma and the Immune Microenvironment
Yawara Kawano et al.
CURRENT CANCER DRUG TARGETS (2017)
Follistatin-like protein 1 contributes to dendritic cell and T-lymphocyte activation in nasopharyngeal carcinoma patients by altering nuclear factor b and Jun N-terminal kinase expression
Hong Wang et al.
CELL BIOCHEMISTRY AND FUNCTION (2016)
Multiple Myeloma: Diagnosis and Treatment
S. Vincent Rajkumar et al.
MAYO CLINIC PROCEEDINGS (2016)
Interleukin-6 Induced Acute Phenotypic Microenvironment Promotes Th1 Anti-Tumor Immunity in Cryo-Thermal Therapy Revealed By Shotgun and Parallel Reaction Monitoring Proteomics
Ting Xue et al.
THERANOSTICS (2016)
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
Kartik Sehgal et al.
BLOOD (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
The targeting of immunosuppressive mechanisms in hematological malignancies
M. H. Andersen
LEUKEMIA (2014)
Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide
Jake Y. Henry et al.
IMMUNOLOGY (2013)
Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity
Aleksandra M. Dudek et al.
FRONTIERS IN IMMUNOLOGY (2013)
IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM
Shirong Li et al.
BLOOD (2011)
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Christine Galustian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
Laure Escoubet-Lozach et al.
CANCER RESEARCH (2009)
Dendritic cell dysfunction in cancer:: A mechanism for immunosuppression
A Pinzon-Charry et al.
IMMUNOLOGY AND CELL BIOLOGY (2005)
Share Paper
